Answers are grounded in this paper and cite their sources.
A survey investigates interest and barriers to adoption of next-generation blood products, suggesting key factors for implementation.
The low familiarity with NGBPs is likely due to the lack of broad regulatory licensing of these products. Cost, clinical value, and health economic considerations will be key to implementing these products.
No takes yet. Share an insight, caveat, or question.
Brown et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: